Merck (MRK) weekly option IV bid into quarter results and outlook

Go back to Merck (MRK) weekly option IV bid into quarter results and outlook

Merck (MRK) Tops Analyst Estimates on Strong Keytruda, Gardasil, and Bridion Sales

July 28, 2022 2:03 PM EDT

Merck's (NYSE: MRK) shares dipped in the early part of Thursday's session after it reported second-quarter earnings.

Profit and revenue topped analyst expectations, but the company's shares fell as low as $87.42 after guidance disappointed investors. The stock has since regained the majority of its initial losses.

Merck posted earnings of $1.87, $0.19 better than the analyst estimate of... More